Lexicon Pharmaceuticals Inc
LXRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.13B
Close$
$-0.39
116.9% downside
Current Fair Value
116.9% downsideOvervalued by 116.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.13 Billion |
|---|---|
| Enterprise Value | $1.09 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 1.07 |
| Outstanding Shares | 400,240,000 |
Return
| Return on Equity | -12.86% |
|---|---|
| Return on Assets | -9.71% |
| Return on Invested Capital | -8.65% |
Valuation & Multiples
| P/E Ratio | -35.71 |
|---|---|
| PEG | 37.25 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 15.72 |
| Enterprise Value to EBIT | -48.88 |
| Enterprise Value to Net Income | -42 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$9.79 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$5.84 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0829▼ 20.21% |
|---|---|
| Total Calls | 1,671,900▲ 115.23% |
| Total Puts | 138,600▼ 37.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 89.07%▲ 17.41% |
|---|---|
| Total Invested | $504.54M▲ 68.47% |
| Investors Holding | 141▲ 14.00% |
ESG Score
No data